AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3400639
Drug: AST-120 (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 (3.2 to 7.2 g/d)
Trial: 29419341
Drug: Self-reported use
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported use of other substances (heroin, cocaine, opiates, oxycodone, benzodiazepines, methamphetamine, phencyclidine, barbiturates)
Trial: 18226671
Drug: 91-day extended-regimen
RxNorm normalized name: benzphetamine hydrochloride Oral Tablet [Regimex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 91-day extended-regimen oral contraceptive (OC) with low-dose ethinyl estradiol (EE)
Trial: 16607146
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (omeprazole, clarithromycin, amoxicillin for 10 days)
Trial: 16607146
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (omeprazole, amoxicillin, metronidazole, bismuth citrate for 10 days)
Trial: 12565981
Drug: Wide local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wide local excision (WLE) and tamoxifen (T) 20 mg daily
Trial: 11004045
Drug: Enalaprilat 1.25
RxNorm normalized name: enalaprilat 1.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat 1.25 mg IV followed by multidose nicardipine 2 mg IV
Trial: 11004045
Drug: Enalaprilat 1.25
RxNorm normalized name: enalaprilat 1.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat 1.25 mg IV followed by labetalol 5 mg IV
Trial: 31888742
Drug: FKB327 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FKB327 40 mg via prefilled syringe (PFS)
Trial: 31888742
Drug: FKB327 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FKB327 40 mg via auto-injector (AI)
Trial: 31888742
Drug: FKB327 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FKB327 40 mg via vial with disposable syringe
Trial: 24158488
Drug: Microbicide gel
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbicide gel adherence in women with ongoing partners
Trial: 24158488
Drug: Microbicide gel
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbicide gel adherence in women with new partners
Trial: 24158488
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of both gel and condom in women with new partners
Trial: 24158488
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of both gel and condom in women with ongoing partners
Trial: 24158488
Drug: High gel
RxNorm normalized name: Tegaderm High Gelling Alginate Dressing 4 inches x 4 inches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High gel adherence in women with ongoing partners
Trial: 22701339
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at a target organ concentration of 2.0 ng/mL
Trial: 20419581
Drug: Child-focused cognitive
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-focused cognitive behavior therapy (CBT) plus parental anxiety management (PAM)
Trial: 20419581
Drug: Child-focused cognitive
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-focused cognitive behavior therapy (CBT)
Trial: 7755384
Drug: C/MF group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C/MF group (Amiparen, 600-800 mL/day)
Trial: 2304739
Drug: Aspirin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1000 mg three times a day)
Trial: 2304739
Drug: Glucamethacin (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucamethacin (140 mg three times a day)
Trial: 2304739
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and Glucamethacin
Trial: 2304739
Drug: Aspirin, Glucamethacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, Glucamethacin, and Placebo
Trial: 23615154
Drug: Movement Music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movement Music Therapy (MMT)
Trial: 19075278
Drug: Immediate docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate docetaxel (75 mg/m² on day 1 every 21 days, maximum of six cycles)
Trial: 8302672
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 25 mg/kg
Trial: 8302672
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 50 mg/kg
Trial: 8302672
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 70 mg/kg
Trial: 8302672
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate doses (25 mg/kg vs 70 mg/kg)
Trial: 3119689
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (single-dose pretreatment)
Trial: 3119689
Drug: Terbutaline (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (single-dose pretreatment, beta 2-agonist)
Trial: 9862408
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo nasal spray
Trial: 12417369
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin intervention regimen (folic acid, vitamins B(6) and B(12))
Trial: 12417369
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin intervention regimen (folic acid, vitamins B(6) and B(12))
Trial: 7742759
Drug: Vancomycin prophylaxis
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin prophylaxis (500 mg x 3 peri-operatively)
Trial: 2045037
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg vaginal tablet (2 x 1) for five consecutive days
Trial: 25841136
Drug: Mean UFH
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean UFH dose difference
Trial: 21067893
Drug: Anterior capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior capsule relaxing incisions with neodymium:YAG laser
Trial: 19807985
Drug: Original azelastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original azelastine nasal spray, 2 sprays/nostril b.i.d.
Trial: 19807985
Drug: Reformulated azelastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated azelastine nasal spray, 2 sprays/nostril b.i.d.
Trial: 19807985
Drug: Placebo, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 sprays/nostril b.i.d.
Trial: 19807985
Drug: Original azelastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original azelastine nasal spray, 1 spray/nostril b.i.d.
Trial: 19807985
Drug: Reformulated azelastine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated azelastine, 1 spray/nostril b.i.d.
Trial: 17702725
Drug: B cell‐driven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B cell‐driven treatment
Trial: 17702725
Drug: Standard protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protocol of four weekly doses of 375 mg/m2
Trial: 15500669
Drug: 20% SLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% SLS solution applied to scalp
Trial: 15500669
Drug: 20% SLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% SLS solution applied to back
Trial: 15500669
Drug: 20% SLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% SLS solution applied to arm
Trial: 9759942
Drug: Ranitidine effervescent
RxNorm normalized name: ranitidine Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine effervescent formulation
Trial: 9759942
Drug: Ranitidine standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine standard formulation
Trial: 7995270
Drug: Other ACE
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other ACE inhibitors
Trial: 22282300
Drug: Milk with
RxNorm normalized name: BETTERMILK with Glytactin 10PE Powder for Suspension (Orange Creme)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk with 250 mg calcium daily
Trial: 22282300
Drug: Soymilk with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soymilk with 250 mg calcium daily
Trial: 18355422
Drug: Rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40 mg plus 20 mL antacid suspension taken simultaneously
Trial: 18355422
Drug: Rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40 mg plus 20 mL antacid suspension taken 2 h after rosuvastatin
Trial: 12848771
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg pseudoephedrine hydrochloride
Trial: 30820338
Drug: Propofol target-controlled
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target-controlled infusion (TCI)
Trial: 31082916
Drug: Surgical resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical resection of the primary tumor followed by systemic therapy (Arm A)
Trial: 31082916
Drug: Primary systemic
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary systemic therapy (Arm B)
Trial: 29231360
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with western medicine (needle‐medicine group)
Trial: 29231360
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine alone (medicine group)
Trial: 22050786
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg + Metformin 1000 mg b.i.d.
Trial: 22050786
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg + Metformin 500 mg b.i.d.
Trial: 22050786
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Sitagliptin + Metformin)
Trial: 15149480
Drug: Recent mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent mental health or addictions treatment utilization
Trial: 9585285
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (3 microg/kg)
Trial: 9585285
Drug: Oral temazepam
RxNorm normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral temazepam (10-20 mg)
Trial: 405730
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg sodium aurothiomalate weekly
Trial: 405730
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sodium aurothiomalate weekly
Trial: 28159194
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment of HTPR patients
Trial: 21699697
Drug: CQ40 (extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQ40 (extended five-day treatment at 40 mg/kg)
Trial: 21699697
Drug: CQ25 (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQ25 (standard three-day treatment at 25 mg/kg)
Trial: 19196886
Drug: Tadalafil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (10 mg o.d.)
Trial: 16234834
Drug: Nucleotide-supplemented formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleotide-supplemented formula (33.5 mg/l)
Trial: 16234834
Drug: Control formula
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formula (10 mg/l NT)
Trial: 9321530
Drug: cA2 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cA2 (5 mg/kg)
Trial: 8404750
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigabatrin (VGB) 1.0 g twice daily for 6 weeks, followed by 1.5 g twice daily for 6 weeks
Trial: 8404750
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigabatrin (VGB) 2 g daily
Trial: 8404750
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigabatrin (VGB) 3 g daily
Trial: 31432705
Drug: Pembrolizumab in
RxNorm normalized name: pembrolizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407)
Trial: 22309355
Drug: Teicoplanin loading
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin loading dose of 12 mg/kg body-weight (group B)
Trial: 22309355
Drug: Teicoplanin loading
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin loading dose of 6 mg/kg body-weight (group A)
Trial: 20649710
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg, single dose)
Trial: 20649710
Drug: Clotrimazole (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (twice daily)
Trial: 15668287
Drug: docetaxel 30
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 30 mg/m(2) and irinotecan 60 mg/m(2) (days 1 and 8)
Trial: 15668287
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m(2) (day 1)
Trial: 15668287
Drug: Combination arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination arm (docetaxel + irinotecan)
Trial: 7901680
Drug: Beta-carotene (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (mean concentration 0.35 microgram/g in cases)
Trial: 7901680
Drug: Alpha-tocopherol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol (mean concentration 193 micrograms/g in cases)
Trial: 7901680
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mean beta-carotene concentration 0.42 microgram/g)
Trial: 2877593
Drug: Vecuronium 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.015 + 0.085 mg/kg body weight at a 3 min interval
Trial: 2877593
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of vecuronium 0.1 mg/kg body weight
Trial: 27636144
Drug: Aprepitant plus
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant plus palonosetron (0.075 mg)
Trial: 27636144
Drug: Aprepitant plus
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant plus ramosetron (0.3 mg)
Trial: 24698672
Drug: Sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (400 mg, twice a day)
Trial: 23955431
Drug: Ad35.CS.01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad35.CS.01 vaccine at 10 (11) vp/mL
Trial: 23955431
Drug: Ad35.CS.01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad35.CS.01 vaccine at 10 (10) vp/mL
Trial: 23955431
Drug: Ad35.CS.01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad35.CS.01 vaccine at 10 (10) vp/mL and 10 (11) vp/mL
Trial: 23955431
Drug: Ad35.CS.01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad35.CS.01 vaccine (all doses)
Trial: 19186342
Drug: Garcinia mangostana
RxNorm normalized name: GARCINIA MANGOSTANA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garcinia mangostana L. pericarp gel (GM gel) applied topically as an adjunct to periodontal treatment
Trial: 19186342
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (scaling and root planing without GM gel application)
Trial: 8839551
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist triptorelin (3.75 mg monthly injections)
Trial: 30200281
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A therapy (BoNT‐A) combined with intensive rehabilitation (IR)
Trial: 24243216
Drug: Oxycodone powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone powder (Oxy API) 30mg
Trial: 19394603
Drug: Intraoperative multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative multimodal analgesia (Diclofenac sodium 100 mg suppository and 0.75% Ropivacaine)
Trial: 17825128
Drug: Monthly bisphosphonate
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly bisphosphonate therapy
Trial: 17825128
Drug: Weekly bisphosphonate
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly bisphosphonate therapy
Trial: 9952362
Drug: Zidovudine combined
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine combined with HIV hyperimmune immunoglobulin (HIVIG) infusions administered monthly during pregnancy and to the neonate at birth
Trial: 9952362
Drug: Zidovudine and
RxNorm normalized name: zidovudine and lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine and intravenous immunoglobulin (IVIG) without HIV antibody
Trial: 2407030
Drug: Long-acting nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting nifedipine (mean daily dose, 52 mg in 2 divided doses)
Trial: 2407030
Drug: Metoprolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (mean daily dose, 155 mg in 2 divided doses)
Trial: 20855672
Drug: Long-pulsed 1064-nm
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-pulsed 1064-nm Nd:YAG laser treatment
Trial: 20017331
Drug: TMZ capsule
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ capsule 150 mg/m2 orally on days 1-5 and CCNU placebo 130 mg/m2 on day 1
Trial: 20017331
Drug: CCNU capsule
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCNU capsule 130 mg/m2 orally on day 1 and TMZ placebo 150 mg/m2 on days 1-5
Trial: 16696391
Drug: Preoperative '3-in-1'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative '3-in-1' Femoral Nerve Block (FNB) using 30 mL of bupivacaine 0.25%
Trial: 16696391
Drug: Postoperative '3-in-1'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative '3-in-1' Femoral Nerve Block (FNB) using 30 mL of bupivacaine 0.25%
Trial: 3436330
Drug: Iopamidol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol (1.5 ml kg‐1)
Trial: 3436330
Drug: Amidotrizoate (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amidotrizoate (1.5 ml kg‐1)
Trial: 3436330
Drug: Amidotrizoate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amidotrizoate (40 ml)
Trial: 3436330
Drug: Iopamidol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol (40 ml)
Trial: 23228561
Drug: Risedronate sodium
RxNorm normalized name: Risedronate Sodium
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Risedronate sodium (35 mg/wk) for 4 months
Trial: 12585724
Drug: L-carnosine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnosine (800 mg daily for 8 weeks)
Trial: 31306076
Drug: Rapid maxillary
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid maxillary expansion (RME) treatment
Trial: 31306076
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (sham appliance)
Trial: 30552531
Drug: Mastery Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mastery Enhancement Therapy
Trial: 30378151
Drug: L-NMMA (n=13)
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (n=13)
Trial: 25932544
Drug: Lacosamide 800
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide 800 mg/day
Trial: 25666151
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg/day
Trial: 19506391
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (1.3, 2.0, and 2.7 mg/m²/day)
Trial: 15375809
Drug: Heat wrap
RxNorm normalized name: Softheat Ultra Back Heat Wrap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat wrap therapy